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Abstract
Background: Antimicrobially pre-treated children with systemic inflammation often pose a diagnostic challenge
to the physician. We aimed to evaluate the additional use of SeptiFast multiplex polymerase chain reaction (PCR)
to identify causative pathogens in children with suspected systemic bacterial or fungal infection.
Methods: Prospective observational study in 39 children with systemic inflammatory response syndrome (SIRS)
under empiric antibiotic treatment. Primary outcome was the rate of positive blood cultures (BC), compared to
the rate of positive SeptiFast (SF) results.
Results: In total, 14 SF-samples yielded positive results, compared to 4 positive BC (p < 0.05). All blood cultures and
13 of 14 positive SF-tests were considered infection. Median time for positive BC was 2 days, and time to definite
result was 6 days, compared to 12 h for SF. Antimicrobial therapy was adapted in 7 of the 14 patients with positive
SeptiFast, and in 3 of the 4 patients with positive BC.
Best predictive power for positive SF shown by receiver-operating characteristic was demonstrated for procalcitonin
PCT (Area under the curve AUC: 0.79), compared to C-reactive protein CRP (AUC: 0.51) and leukocyte count
(AUC: 0.46). A procalcitonin threshold of 0.89 ng/ml yielded a sensitivity of 0.82 and a specifity of 0.7. Children
with a positive SeptiFast result on day 0 had a significantly higher risk to require treatment on the Pediatric
Intensive Care Unit or to be deceased on day 30 (Odds-Ratio 8.62 (CI 1.44-51.72).
Conclusions: The additional testing with SeptiFast in antimicrobially pre-treated children with systemic
inflammation enhances the rate of pathogen detection. The influence of multiplex PCR on clinically
relevant outcome parameters has to be further evaluated. (Trial registration: DRKS00004694)
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Background
In suspected serious bacterial or fungal infection, particu-
larly sepsis, antimicrobial treatment is commonly initiated
empirically. If necessary, therapy is modified according to
microbial results. Today, blood cultures are considered
diagnostic gold standard in sepsis to identify pathogens and
to test possible resistance. Unfortunately, gram stainings
are usually available earliest after 12–15 h, and definitive
results of culture not before 48 h. As time is crucial in
sepsis, this delay in diagnostics and hence correct treatment
might have detrimental consequences for the patient [1–4].
Additionally, often neither bacteria nor fungus can be
found in clinically suspected sepsis in children. To produce
reliable results in blood cultures, a minimum number of
viable pathogens are required. If the patient is already under
antimicrobial treatment, the quantity of circulating patho-
gens is substantially reduced. And medical staff often faces
difficulties in obtaining sufficient amounts of blood in small
infants, which is another factor potentially contributing to
failure of blood culture [5].
Differentiation between a Systemic Inflammatory Re-
sponse Syndrome (SIRS) due to an infection and SIRS due
to other reasons can become a true challenge. Chronically
ill children are often hospitalized for long periods of time.
They are prone to SIRS caused by e. g. viral infections, the
underlying disease itself, subileus or ileus, or rejection after
transplantation. Again, delayed or wrong diagnosis might
be detrimental for the patient. Therefore, much hope is
being put into newer diagnostic technologies to improve
detection rates of infectious pathogens or to exclude bacte-
rial/fungal infections.
SeptiFast is a multiplex polymerase chain reaction
(PCR) based method, able to identify desoxyribonucleic
acid (DNA) of 25 different bacteria and fungi. Major
advantage of this method is the fact that for PCR only very
small amounts of pathogens are needed. And, as it is not
dependent on growth of bacteria no viable material is
needed which means that also killed bacteria can still be
detected. Causative pathogens can be detected even under
antimicrobial therapy, when viable bacteria or fungi are
not present for cultivation anymore.
Based on these considerations, we initialized a prospec-
tive observational study in children with systemic inflam-
mation and under antimicrobial treatment. We compared
the rates of successful pathogen identification by BC to
those by SeptiFast. The primary goal of the study was the
rate of positive SF tests compared to the rate of positive
BC.
Methods
Patients: Infants, children, and adolescents were included in
this prospective observational study, if they were clinically
diagnosed with Systemic Inflammatory Response Syndrome
(SIRS) and pre-treated with systemic antibiotics. Time
threshold for pre-treatment was either more than 48 h of
antibiotic therapy or at least two doses, if the patient was
admitted to the pediatric intensive care unit (PICU). This
second inclusion criterion was chosen, because it was
assumed that a sicker patient would possibly benefit from
early diagnosis. SIRS was defined using the International
Pediatric Sepsis Consensus Conference criteria from
2005 [6]. The only exclusion criteria were prematurity
of 37 weeks or less and age below 28 days.
Outcome criteria: Primary outcome criterion was the
rate of positive BC compared to the rate of positive SF
results.
Secondary outcome parameters were time to definite
result of BC and SF, number of antimicrobial therapy
changes according to BC and SF results, and the predic-
tive power for positive SF of additional biomarkers such
as C-reactive protein, leukocyte count and procalcitonin.
Additionally, we documented the treatment status at day
30 according to the following categories: 1) death, 2) still
on pediatric intensive care unit, 3) transferred to or still
staying on peripheral ward, 4) discharged from hospital.
Study protocol: In children with SIRS and antibiotic pre-
treatment, who were enrolled in the study, personal data
including duration of antibiotic therapy and its modification
were documented. Vital parameters (heart rate, respiratory
rate, body temperature) and infection biomarkers from
blood (C-reactive protein CRP, leukocyte count and procal-
citonin PCT) were recorded on day 0, day 4-6 and day 30,
if available.
Antibiotic treatment, number, and site of BC taken
(central versus peripheral) as well as the amount of blood
drawn for blood cultures were left to the decision of the
attending physician. A manual with advices for optimum
BC diagnostics was handed to all participating physicians.
The physician in charge assessed all positive BC and SF
results for infection, contamination, or whether they were
not assessable (n/a). There was no treatment algorithm
for a positive SF or BC result provided.
Blood sampling: Blood samples were taken from a
peripheral vein or from a central venous line. For SF, at
least 1.5 ml blood was collected and charged with ethylen-
diaminetetraacetic acid. Blood culture bottles were inocu-
lated with 1–10 ml blood, depending on the age of the
child and on the type of bottle used (aerobic/anaerobic or
both). If possible, paired samples were taken for SF and
BC, if not, a second sample was taken as soon as possible
not exceeding a delay of 24 h. In all patients, a single SF
sample was taken.
Blood culture sample: Depending on the age of the
patient, samples were inoculated into Bactec Peds Plus/F
(children younger than 36 months) or Bactec Plus/F
aerobic and anaerobic bottles (Bactec, Becton Dickinson
GmbH, Germany). BCs were incubated for up to 5 days at
36 °C. In case of a positive blood culture result, aliquots
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were taken for subculture on solid media, Gram-stain and
susceptibility-testing via MicroScan WalkAway (Siemens
Healthcare Diagnostics, Germany).
Real-Time multiplex PCR: The SeptiFast real-time PCR
is capable of the amplification and detection of 25 micro-
organisms (see Table 1, SeptiFast Masterlist) by using the
internal transcribed spacer region of the microorganisms
as specific target. A detailed description of the assay has
been given elsewhere [7]. Briefly, the assay follows three
steps: 1) specimen preparation by mechanical lysis and
purification of (DNA), 2) Real-time PCR amplification of
target DNA in three parallel reactions (Gram positive,
Gram negative, fungi) and subsequent detection of PCR
products by specific hybridization probes, and 3) auto-
mated identification of species and controls [7].
According to the manufacturer's instruction, a sample
of 1.5 ml whole blood was used. Lysis was performed in
a MagNALyzer® instrument (Roche Diagnostics GmbH,
Mannheim, Germany) and DNA was prepared using the
SeptiFast Prep Kit Mgrade (Roche, Diagnostics GmbH,
Mannheim, Germany). For PCR reaction, the LightCy-
cler®SeptiFast Kit (Roche Diagnostics GmbH, Mannheim,
Germany) and the LightCycler®2.0 Instrument were used.
Identification of amplification products was performed
using the SeptiFast® Identification Software V2.0 (Roche
Diagnostics GmbH, Mannheim, Germany).
Pathogen definition/contamination: Coagulase-negative
staphylococci were considered as infections, if they were
detected in two independent BCs or in one blood culture,
and the clinical picture and laboratory parameter supported
an infection. For all other bacteria, BC was scored positive,
if one BC sample yielded a pathogen, even if more than one
BC was drawn. Microorganisms were considered as patho-
gens, if they were detected in BC and in SF. In case of
discordant results of BC and SF, results from other micro-
biological assays like urine cultures, bronchial secretion or
swabs were analysed. In case the pathogen was not detected
in any other material, imaging and the clinical picture as
well as the propensity of the species as underlying agent of
sepsis were included in the interpretation. An infection
with the pathogen was also assumed, if the patient reco-
vered after adjustment of the antimicrobial therapy based
on the results of BC and/or SF.
Statistical analysis
According to prior data [8] of a retrospective study on the
comparison of BC and SF, we performed a sample calcu-
lation with 90 % power of a two-sided exact test on a
significance level of 0.05 for the superiority of the rate of
pathogen detection by SF over the rate of pathogen detec-
tion by BC. The estimated number of patients was 61. As
enrolment was much slower than expected we repeated
sample size calculation after two years with 80 % power
and revealed a number of 40 patients. Therefore we
stopped recruitment after three years and 39 patients.
All data are presented as median and range. Analysis of
categorical variables was performed using Chi-square test.
Two independent groups were tested by Mann-Whitney-U
test. Predictive power of biomarkers for positive SF was
assessed by receiver-operating characteristic curves (ROC
curves) and calculation of the area under the curve (AUC).
P < 0.05 was considered statistically significant. The risk of
an adverse outcome on day 30 is given as Odds-Ratio (OR)
with 95 % confidence interval (CI).
Analysis was performed using the SPSS 22 Statistical
package (IBM, Armonk, NY, USA).
Ethics, consent and permissions
The study protocol was approved by the local ethics
committee of the University Hospital Essen (10-4369),
and all parents or legal guardians gave written informed
consent.
Results
39 children with an episode of SIRS were included in the
study, 23 female and 16 male. Median age was 5 years
(range 0.1-18 years). Seventeen patients had an underlying
oncologic disease, 10 were post transplantation either liver
or kidney, 5 had neurological disease, 1 had a gastro-
enterological disease and 6 were treated due to general
pediatric illness. Because of the underlying disease or
immunosuppressive treatment, 27 patients were classified
as immunocompromised. Twenty-five children (64 %)
were treated on the Pediatric Intensive Care Unit (PICU)
at the time of SeptiFast and blood culture sampling. Of
those, 14 patients were mechanically ventilated, and 7
received inotropes or vasopressors.
In thirty patients, blood samples (SF and BC) were taken
from central venous catheters (CVC), in 8 patients from
peripheral blood and in one from both (paired blood
Table 1 SeptiFast Master List (Lehmann 2008)
Gram negative Gram positive Fungi






Serratia marcescens Streptococcus pneumoniae Candida parapsilosis
Enterobacter
(cloacae/ aerogenes)
Streptococcus species Candida krusei
Proteus mirabilis Enterococcus faecium Candida glabrata
Pseudomonas
aeruginosa





Coagulase-negative staphylococci (S. epidermidis, S. haemolyticus)
Streptococcus species (including e.g., S. pyogenes, S. agalactiae, S. mitis)
Gies et al. BMC Infectious Diseases  (2016) 16:378 Page 3 of 8
cultures). The number of blood culture samples taken
within 24 h was at median 2 (range 1–8) with the total
number of 71 BC in 39 patients. For 17 children, only one
BC sample was inoculated, for 22 children, two or more
BC samples were inoculated. At the time of blood-
sampling, median antibiotic therapy had been carried out
for 6 days (range 1–56) and consisted of 2 intravenous
antibiotics (range 1–5). Eleven patients received additional
intravenous antifungal therapy. Median values of inflam-
matory biomarkers at the time of blood sampling were as
follows: CRP 8.5 mg/dl (range 0.5–39.8); procalcitonin
(n = 34) 0.75 ng/ml (range 0.1–72.01); leukocyte count
3.49/nl (range 0.04–59.4).
BC revealed positive results in 4 patients (10 %),
whereas SF were positive in 14 (36 %) (χ2: p < 0.05). In 3
out of 14 patients with positive SF results, two patho-
gens were detected comprising altogether 17 pathogens.
Two identical SF and BC results were identified: Klebsi-
ella pneumoniae and coagulase-negative staphylococci
(see Table 2). Including these identical results, pathogens
detected by SF, were also found by other microbiological
assays in 7 cases (see Table 2), pathogens detected by
blood-culture were found in 2 cases. The attending phy-
sician assessed all positive blood-culture results as infec-
tions. After considering the concordant results and other
findings (e.g. clinical picture and imaging), 15 of the 17
pathogens detected by SF were rated as causative patho-
gens. The remaining 2 positive SF results were rated as
not assessable.
Therapy was changed ten times in 7 patients following
a positive test result (9 times change of antimicrobial
therapy, 1 new central venous catheter). Positive SF
results led to a change in antimicrobial treatment in 7 of
the 14 SF-positive patients (18 % of all patients, 50 % of
positive SF results). Positive BCs resulted in a change in
3 of the 4 patients (8 % of all patients, 75 % of positive
blood-cultures). One of these changes was explained by
a concurrent SF and BC result. In another case, antibiotic
therapy was changed twice in one patient following the
detection of different pathogens in SF and BC. The
reported changes comprised additional medication in 5,
change of drug in 3 patients, and discontinuation of one
drug in one patient (for details see Table 2).
Time until definite result from BC overall was 6 days
(range 1–7), dependent on the result. While results of
positive cultures were available after 2 days (range 1–3),
negative results were finally reported after 6 days (range
4–7). Median time until SF result was overall 12 (range
1–73) hours, after the blood sample was drawn. Time
until result of the SF test depended on the time of the
testing, as SFs were only performed once a day and only
on working days due to technical and personal reasons. In
case blood sampling was carried out on a working day,
results were reported after a median of 8 h (range 1–48).
If the sample was taken on a weekend or on a Friday after
regular working hours of the laboratory, the result was
reported after a median of 25 h (range 11.5–73).
There were no statistically significant differences in CRP
or leukocyte counts between children with positive SF and
children with negative SF, but in procalcitonin (see Table 3).
We plotted ROC curves for CRP, leukocyte count, and
procalcitonin as possible predictive biomarkers for a posi-
tive SF result (Fig. 1). The resulting AUC was highest for
PCT (0.79) and low for CRP (0.51) and leukocyte count
(0.46). A cut-off point of 0.89 ng/ml for PCT showed a
sensitivity of 0.82 and a specifity of 0.7 for a positive SF
result.
On day 30 after BC and SF testing, 2 patients had died
(both SF positive), 6 patients (4 SF positive, 2 SF negative)
were still treated on the pediatric intensive care unit, 13
(6 SF positive) were treated on a peripheral ward and 18
(2 SF positive) were discharged from hospital. Children,
who had a positive SF result on day 0, were more likely to
die or be on the PICU on day 30 than children with a
negative SF (χ2: p < 0.05; (OR: 8.62 (CI 1.44–51.72)).
Discussion
This is the first prospective trial applying SeptiFast in
children with SIRS already under antimicrobial therapy. In
our study, SeptiFast revealed significantly more positive
results than blood cultures. In 7/39 patients, antimicrobial
therapy was changed based on positive SF results. Time to
obtain definite SeptiFast results was significantly shorter
than that for blood cultures.
Several studies using SeptiFast were carried out mainly
in adults and scrutinizing different clinical circumstances
(e. g. febrile neutropenia, suspected sepsis). They could
show that not only the total number of pathogens found
was higher, but also pathogen detection delay was improved
by adding a PCR based diagnostic tool to the gold standard
of blood culture [9–13]. Three retrospective cohort studies
in heterogeneous groups of pediatric patients revealed
similar results [8, 14, 15]. Our approach is new, thus focu-
sing on children with SIRS, who are already under anti-
biotic treatment, which makes pathogen detection tricky.
Children with SIRS under antibiotic therapy remain a
diagnostic challenge. The majority suffers from chronic
diseases associated with long hospitalizations, compli-
cations, and side effects due to therapy. Our study group
included many immunocompromised patients due to im-
munosuppressive treatment or underlying disease. These
patients are at an increased risk of infection and septi-
caemia, and severe sepsis was shown to have a higher case
fatality rate [16]. This risk produces increased awareness
of the treating physicians making severe infection a more
likely treatment hypothesis. However, other reasons for
SIRS than infection, e. g. transfusions, surgery or the under-
lying disease itself have to be considered. Additional tools
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Table 2 Positive blood cultures and SeptiFast results, physicians’ judgement, clinical findings and the resulting changes in antimicrobial therapy
BC SeptiFast Judgement Significant clinical
information



























9 CONS Enterobacter cloacae Co-infection Neuropediatric,




SF: Meropenem instead of
cefotaxime
BC: Additionally vancomycin




15 Klebsiella pneumoniae Infection After bone










Second BC: CONS SF: Additionally fluconazole
19 Klebsiella pneumoniae Infection After liver tx, PICU,











26 Streptococcus spp. Infection ALL, PICU, MV, 38.8 °C PCT 22.52 ng/ml
CRP 39.8 mg/dl
WBC 0.04/nl
BC 2 days before study:
Streptococcus spp.
No (under meropenem)







BC: New CVC; additionally
caspofungin,
SF: linezolid instead of
vancomycin
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39 Klebsiella pneumoniae Klebsiella pneumoniae,
Streptococcus spp.





Bile: Klebsiella pneumoniae BC+ SF:
Discontinuation of vancomycin
BC blood culture, SF SeptiFast, MV mechanical ventilation, VP vasopressor, PICU Pediatric Intensive Care Unit, tx transplantation, BPD bronchopulmonary dysplasia, CONS coagulase negative staphylococci, ALL acute














to differentiate between inflammation and infection, but
also between viral and bacterial cause, could assure the
physician, and help to guide therapy. Blood cultures are
often not helpful, as negative results cannot entirely rule
out infection. And results are often too delayed to wait for,
in order to start targeted therapy. Bacteria blood concentra-
tions in children might have been substantially reduced by
antibiotics, thus making bacteria cultivation impossible. In
addition, the amount of blood in small infants is often
limited [5]. As successful cultivation depends on the quan-
tity of bacteria, namely cc of blood, administered to the
blood culture, small amounts of blood are another impor-
tant limitation of blood cultures especially in children.
A study on immunocompromised children with febrile
neutropenia could show that positive blood culture rates
exceeded 10 %, when repeated blood cultures were ob-
tained [17], although initial blood culture was negative. As
the concentration of bacteria in blood varies, it might inter-
mittently be below detection threshold. We hypothesize
that SF might have identified the causative pathogen
already in the initial diagnosis. In our clinical setting, Septi-
Fast enhanced not only the rate of pathogen detection, but
also led to antibiotic treatment modifications.
Susceptibility testing is indispensable, as it allows a true
targeted therapy. Multiplex real-time PCR can therefore
not replace BC, as susceptibility testing is reserved to
blood culture only.
Limitations of the present study are a restricted number
of blood cultures obtained, and the fact that the vast
majority of blood cultures were taken from central cathe-
ters, and not from peripheral veins. As no data were drawn,
concerning the amount of blood administered to blood
cultures, it cannot be excluded that the rate of positive BC
might have been higher with larger blood volumes. Another
limitation of this study is the lack of an implemented
algorithm for the interpretation of BC and SF results as
Table 3 Comparison of patient data for SeptiFast-positive and
SeptiFast-negative group
SF positive SF negative
Procalcitonin (ng/ml) 1.87 (0.53–72) 0.58 (0.1–32) p = 0.008
C-reactive protein
(mg/dl)
9.35 (0.5–39.8) 8.5 (1.9–30.7) p = 0.24
Days of antibiotic
pretreatment
3 (1–56) 9 (1–54) p = 0.09
Age (years) 4 (0.03–18) 6.3 (0.01–17) p = 0.89
Maximum
temperature (°C)
38.6 (34–40.5) 39 (37.2–40.1) p = 0.06
Leukocyte count (/nl) 3.43 (0.04–24.1) 5.4 (0.04–59.6) p = 0.76
Fig. 1 ROC plots for CRP, PCT and leukocyte count predicting positive SF. ROC = Receiver Operating Curves, CRP = C-reactive protein,
PCT = procalcitonin; “ties” explain two equal values
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present in other studies [14]. For example, time to positivity
of blood cultures was not provided to the treating phy-
sician, and therefore not available for assessment of clinical
relevance of BC. Certainly, therapy decisions were also
based on other laboratory data and clinical conditions as
reported in other studies [11, 12, 14]. In some cases,
discrepancy in clinical findings and the detected pathogen
caused physicians to follow their clinical experience, rather
than a test result. Physicians were then left with the inse-
curity that SeptiFast does not discriminate between DNA
from viable and dead microorganisms. Tsalik et al have
shown a good correlation between the presence of DNA
and the infection status of adult patients [18]. Neverthe-
less, further studies are needed to verify the clinical rele-
vance of microbial DNA in blood samples.
In all studies, time to SF result was significantly shorter
than time to positive BC result. Even in an optimal setting
with sufficient amounts of blood and an immediate 24 h BC
result transmission, we still have to face an important time
gap between BC and SF. It must be stressed that also SF
requires 6–12 h for a result. And a delay of 6 to 12 h, until
beginning an adequate antimicrobial therapy, might simply
be too long. Therefore, in a variety of clinical situations,
empirical therapy is started earlier based on the individual
patients´ symptoms, disease severity, and local antimicrobial
resistance patterns. In instable patients, clinical decisions
must be drawn immediately, whereas in stable patients,
waiting for SF results might be justifiable. Whether the en-
hanced rate of pathogen detection with molecular methods
can improve the patients´ outcome in terms of morbidity
and mortality still has to be determined. Another interesting
question is: Can negative results help to avoid unnecessary
anti-infective therapies? In our patients a positive SF result
was significantly correlated with an increased risk of death
or prolonged stay on the PICU on day 30. Nevertheless, it
remains uncertain if a positive SF can be counted as
independent impact factor on worse outcome. It possibly
just indicated a sicker patient at time of diagnosis.
As SF is a costly test, we evaluated parameters possibly
predicting a positive SF result. Classical biomarkers, such
as C-reactive protein and leukocyte count, were not able
to predict relevant bacterial or fungal infections. AUC for
these biomarkers revealed values of merely 0.5, which
reflects the discriminative power of throwing a coin. In
contrast, the prognostic value of procalcitonin (PCT) was
statistically significant. Children with a positive SF had a
significantly higher PCT than those with negative SF.
Recent studies in adults support our results, indicating
a significant association of the PCT level and a positive
SF result, but differing in the PCT threshold value
(≥0,5 ng/ml [19] />0.37 ng/ml [20]). These findings are in
line with other studies that prefer PCT to other biomarkers
in the diagnosis of bacterial bloodstream infections. A
recent review revealed best sensitivity and specificity for
ruling out severe bacterial infection at a PCT level of
≤0.5 ng/ml in children. Levels higher than 2 ng/ml were a
significant indicator for septicaemia [21]. However, to our
knowledge, PCT is still less frequently used in children.
Conclusion
In our study, SeptiFast detected infectious pathogens in
more than one third of patients with SIRS under antimicro-
bial therapy. And it was superior to blood cultures concern-
ing detection rates and time delay. However, the true
impact on medical management and patient outcome can-
not be determined yet. Therefore, SeptiFast requires further
clinical evaluation.
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